Laura M. Heiser

Subtype and pathway specific responses to anticancer compounds in breast cancer

Laura M. Heiser, Anguraj Sadanandam, Wen‐Lin Kuo et al. · Proceedings of the National Academy of Sciences · 2011 · 501 citations

Drug Target, Breast Oncology, Chemoprevention Strategy +17

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition

Olga K. Mirzoeva, Debopriya Das, Laura M. Heiser et al. · Cancer Research · 2009 · 386 citations · Full text

Metrics other than potency reveal systematic variation in responses to cancer drugs

Mohammad Fallahi‐Sichani, Saman Honarnejad, Laura M. Heiser et al. · Nature Chemical Biology · 2013 · 320 citations · Full text

Therapeutic Drug Monitoring, Oncology, Medicine +8

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

Eric A. Collisson, Christy L. Trejo, Jillian M. Silva et al. · Cancer Discovery · 2012 · 316 citations · Full text

Modeling precision treatment of breast cancer

Anneleen Daemen, Obi L. Griffith, Laura M. Heiser et al. · Genome biology · 2013 · 312 citations · Full text